Pandion Therapeutics
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$58.0m | Series A | ||
* | $80.0m | Series B | |
N/A | $135m Valuation: $513m | IPO | |
$1.9b Valuation: $1.9b | Acquisition | ||
Total Funding | $138m |
Related Content
Recent News about Pandion Therapeutics
EditPandion Therapeutics is a biotechnology company focused on developing innovative treatments for autoimmune and inflammatory diseases. The company operates in the biopharmaceutical market, serving patients and healthcare providers. Pandion's business model revolves around its proprietary TALON (Therapeutic Autoimmune reguLatOry proteiN) drug design platform, which allows for the creation of modular precision medicine therapeutics. These therapeutics are engineered to achieve lasting therapeutic outcomes by selectively modulating the immune system. The company generates revenue through the development and potential commercialization of its drug candidates, as well as through partnerships and collaborations with other pharmaceutical companies.
Keywords: biotechnology, autoimmune, inflammatory, TALON, precision medicine, immunomodulatory, therapeutics, drug development, healthcare, biopharmaceutical.